Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Nanomedicine (Lond). 2012 Dec;7(12):1895–1906. doi: 10.2217/nnm.12.160

Figure 3. Representative examples of enhanced nanoparticle targeting to EGF receptors using nanoparticle decoration with anti-EGF receptor antibody fragments.

Figure 3

(A) Cell viability assay shows a significant decrease in cell viability following treatment with varying DDP concentrations delivered via anti-EGF receptor fragment-labeled nanoparticles, compared with nontargeted nanoparticles or free drug. (Bi) Anti-EGF receptor fragment-labeled red fluorescent polymeric micelles undergo higher internalization compared with (Bii) the nontargeted formulation.

*p < 0.05; **p < 0.01.

DDP: Cisplatin; EHDDP: EGF receptor-targeted–heparin–cisplatin; HDDP: Heparin–cisplatin; Pt: Platinum.

Reproduced with permission from [48,52].

For color images see online at www.futuremedicine.com/doi/10.2217/nnm.12.160.